Last reviewed · How we verify

Lutetium[177Lu] Oxodotreotide Injection

Sinotau Pharmaceutical Group · Phase 3 active Small molecule

Lutetium[177Lu] Oxodotreotide Injection is a Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) Small molecule drug developed by Sinotau Pharmaceutical Group. It is currently in Phase 3 development for Neuroendocrine tumors (NET) expressing somatostatin receptors, Gastroenteropancreatic neuroendocrine tumors (GEP-NET). Also known as: 177Lu-DOTA0-Tyr3-Octreotate.

Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.

Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy. Used for Neuroendocrine tumors (NET) expressing somatostatin receptors, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).

At a glance

Generic nameLutetium[177Lu] Oxodotreotide Injection
Also known as177Lu-DOTA0-Tyr3-Octreotate
SponsorSinotau Pharmaceutical Group
Drug classRadiolabeled peptide; peptide receptor radionuclide therapy (PRRT)
TargetSomatostatin receptor 2 (SSTR2)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

This radiopharmaceutical combines lutetium-177, a beta-emitting radionuclide, with oxodotreotide, a somatostatin receptor 2 (SSTR2)-targeting peptide. The peptide binds with high affinity to somatostatin receptors overexpressed on neuroendocrine tumor cells, allowing the radioactive lutetium-177 to deliver localized cytotoxic radiation directly to tumor tissue while minimizing exposure to healthy cells.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lutetium[177Lu] Oxodotreotide Injection

What is Lutetium[177Lu] Oxodotreotide Injection?

Lutetium[177Lu] Oxodotreotide Injection is a Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) drug developed by Sinotau Pharmaceutical Group, indicated for Neuroendocrine tumors (NET) expressing somatostatin receptors, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).

How does Lutetium[177Lu] Oxodotreotide Injection work?

Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.

What is Lutetium[177Lu] Oxodotreotide Injection used for?

Lutetium[177Lu] Oxodotreotide Injection is indicated for Neuroendocrine tumors (NET) expressing somatostatin receptors, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).

Who makes Lutetium[177Lu] Oxodotreotide Injection?

Lutetium[177Lu] Oxodotreotide Injection is developed by Sinotau Pharmaceutical Group (see full Sinotau Pharmaceutical Group pipeline at /company/sinotau-pharmaceutical-group).

Is Lutetium[177Lu] Oxodotreotide Injection also known as anything else?

Lutetium[177Lu] Oxodotreotide Injection is also known as 177Lu-DOTA0-Tyr3-Octreotate.

What drug class is Lutetium[177Lu] Oxodotreotide Injection in?

Lutetium[177Lu] Oxodotreotide Injection belongs to the Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) class. See all Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) drugs at /class/radiolabeled-peptide-peptide-receptor-radionuclide-therapy-prrt.

What development phase is Lutetium[177Lu] Oxodotreotide Injection in?

Lutetium[177Lu] Oxodotreotide Injection is in Phase 3.

What are the side effects of Lutetium[177Lu] Oxodotreotide Injection?

Common side effects of Lutetium[177Lu] Oxodotreotide Injection include Hematologic toxicity (anemia, thrombocytopenia, leukopenia), Nausea and vomiting, Fatigue, Renal toxicity, Hepatic toxicity.

What does Lutetium[177Lu] Oxodotreotide Injection target?

Lutetium[177Lu] Oxodotreotide Injection targets Somatostatin receptor 2 (SSTR2) and is a Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT).

Related